Tag: Covid19 Essential Business
Avalon GloboCare (NASDAQ: AVCO) could be one of the most undervalued Biotech stocks that has disruptive technology in CAR-T immunotherapy that applies to both cancer (specifically leukemia) as well as COVID-19. Avalon uses a proprietary S-Layer “surface layer” technology to develop an intranasal vaccine that attaches to the mucosal membrane CEO Dr. David Jin pointed out.
A diamond in the rough and under the radar potential outperformer is a company by the name of Avalon GloboCare (NASDAQ: AVCO) who are using a proprietary S-Layer “surface layer” technology to develop an intranasal vaccine that attaches to the mucosal membrane CEO Dr. David Jin pointed out.
Avalon GloboCare is in the process of establishing a state-of-the-art research facility, the Christian Doppler Laboratory, located on the BOKU campus in Vienna, Austria, under the scientific leadership of Professor Eva-Kathrin Ehmoser, the Head of BOKU’s Institute for Synthetic Bioarchitectures and Professor Uwe Sleytr, a member of the Austrian Academy of Sciences.
Another solid player in the COVID-19 test kit market is Avalon GloboCare (NASDAQ: AVCO) who recently partnered with Adial Pharmaceuticals (NASDAQ: ADIL) announcing a Strategic Collaboration for Global Distribution of COVID-19 Point-of-Care Antibody Rapid Test Devices
As the war against COVID-19 wages on there are a large number of Bio-Tech players racing to get an effective vaccine to market and with the new South African strand there is a concern with who’s will be effective. Another company to keep your eye on is Avalon GloboCare (NASDAQ: AVCO) who are using a proprietary S-Layer “surface layer” technology to develop an intranasal vaccine that attaches to the mucosal membrane CEO Dr. David Jin pointed out.
With the potential of a ‘twindemic’ of influenza and SARS-CoV-2 during fall and winter, Avalon GloboCare (NASDAQ: AVCO) is also planning to conjugate the S-layer matrix with an antigenic signature from both SARS-CoV-2 and the influenza virus for one spray that, if proven effective, would provide protective immunity against both viruses. Novarex trades 100X higher price then Avalon and needs the vaccine to be administered twice as opposed to once.
Avalon GloboCare Corp. (NASDAQ: AVCO) a leader in cell-based technology, is launching two major clinical trials to test its blood filtration technology to combat ‘cytokine storms’ induced in some COVID-19 patients and nasal spray vaccine to prevent COVID-19.
If you want to get into crypto, there are not many options, so the companies with direct exposure have been on a run. Riot Blockchain (NASDQ: RIOT), recently ran 800% from $4.00 to nearly $28.00 in about 8 days and Grayscale Bitcoin Trust (OTC Pink: GBTC), ran 500% from $10 to nearly $50 before a pullback yesterday.
CytoDyn Inc. (OTCMKTS: CYDY) may have given one of its last updates as an OTC company yesterday and revealed a number of positive surprises. They could be saying hello NASDAQ, and hello EUA in the course of the next couple of weeks.
Epazz, Inc. (OTC Pink: EPAZ) recently announced that it is working with Greenheart CBD Hemp company in developing their smart contracts for their IEO (Initial Exchange Offering), and the market seems to be reacting well to their entry into this space.